Bioavailability of oral cyclosporine in healthy Mexican volunteers: Evidence for interethnic variability

被引:27
作者
PalmaAguirre, JA
GonzalezLlaven, J
FloresMurrieta, FJ
CastanedaHernandez, G
机构
[1] INST POLITECN NACL,CTR INVEST & ESTUDIOS AVANZADOS,DEPT FARMACOL & TOXICOL,SECC TERAPEUT EXPT,MEXICO CITY 14000,DF,MEXICO
[2] INST MEXICANO SEGURO SOCIAL,DEPT PHARMACOL STUDIES,UNIDAD CONTROL TECN INSUMOS,MEXICO CITY,DF,MEXICO
[3] HOSP ESPECIALIDADES CTR MED LA RAZA,INST MEXICANO SEGURO SOCIAL,CTR MED RAZA,HEMATOL SERV,MEXICO CITY,DF,MEXICO
关键词
D O I
10.1002/j.1552-4604.1997.tb04346.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The existence of population variations in cyclosporine pharmacokinetics could be expected, as this drug, similar to nifedipine, is biotransformed by cytochrome P-450 subfamily 3A4, and the existence of interethnic variability in nifedipine disposition has been demonstrated previously. The bioavailability of oral cyclosporine rr as studied in 23 healthy Mexican volunteers receiving 7.5-mg/kg doses of cyclosporine. Blood samples were drawn over 24 hours, and concentration of cyclosporine in tt hole blood rt as determined by a radioimmunoassay using monoclonal antibodies specific for the unchanged drug. The bioavailability of cyclosporine exhibited wide interindividual variability. Maximum concentration (C-max) ranged from 528 ng/mL to 2,689 ng/mL, area under the concentration-time curve (AUG) ranged from 6,550 ng.hr/mL to 18,562 ng.hr/mL, and time to reach C-max (t(max)) ranged from 1 to 8 hours. Half-life (t(1/2)) exhibited less important variations, ranging from 4.4 to 9.1 hours. The bioavailability of oral cyclosporine in Mexicans was higher than that reported for white populations under similar conditions. The present results suggest the existence of interethnic variability in the pharmacokinetics of cyclosporine, as is the case with nifedipine.
引用
收藏
页码:630 / 634
页数:5
相关论文
共 24 条
  • [1] ETHNIC-DIFFERENCES IN THE PHARMACOKINETICS OF ORAL NIFEDIPINE
    AHSAN, CH
    RENWICK, AG
    MACKLIN, B
    CHALLENOR, VF
    WALLER, DG
    GEORGE, CF
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (04) : 399 - 403
  • [2] THE INFLUENCES OF DOSE AND ETHNIC-ORIGINS ON THE PHARMACOKINETICS OF NIFEDIPINE
    AHSAN, CH
    RENWICK, AG
    WALLER, DG
    CHALLENOR, VF
    GEORGE, CF
    AMANULLAH, M
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (03) : 329 - 338
  • [3] GRAPEFRUIT JUICE AND DRUGS - HOW SIGNIFICANT IS THE INTERACTION
    BAILEY, DG
    ARNOLD, JMO
    SPENCE, JD
    [J]. CLINICAL PHARMACOKINETICS, 1994, 26 (02) : 91 - 98
  • [4] CastanedaHernandez G, 1996, BRIT J CLIN PHARMACO, V41, P433
  • [5] PHARMACOKINETICS OF ORAL NIFEDIPINE IN DIFFERENT POPULATIONS
    CASTANEDAHERNANDEZ, G
    HOYOVADILLO, C
    PALMAAGUIRRE, JA
    FLORESMURRIETA, FJ
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 33 (02) : 140 - 145
  • [6] METABOLIC POLYMORPHISMS
    DALY, AK
    CHOLERTON, S
    GREGORY, W
    IDLE, JR
    [J]. PHARMACOLOGY & THERAPEUTICS, 1993, 57 (2-3) : 129 - 160
  • [7] DOSE-RESPONSE VARIATION AMONG DIFFERENT POPULATIONS
    DARMANSJAH, I
    MUCHTAR, A
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (05) : 449 - 452
  • [8] DISPOSITION OF INTRAVENOUS AND ORAL CYCLOSPORINE AFTER ADMINISTRATION WITH GRAPEFRUIT JUICE
    DUCHARME, MP
    WARBASSE, LH
    EDWARDS, DJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (05) : 485 - 491
  • [9] GUENGERICH FP, 1990, CARCINOGENESIS, V11, P2275, DOI 10.1093/carcin/11.12.2275
  • [10] EFFECT OF FOOD ON THE PHARMACOKINETICS OF CYCLOSPORINE IN HEALTHY-SUBJECTS FOLLOWING ORAL AND INTRAVENOUS ADMINISTRATION
    GUPTA, SK
    MANFRO, RC
    TOMLANOVICH, SJ
    GAMBERTOGLIO, JG
    GAROVOY, MR
    BENET, LZ
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (07) : 643 - 653